Amgen (NasdaqGS:AMGN) FY 2025 Conference December 03, 2025 01:45 PM ET Company ParticipantsCasey Capparelli - VP of Investor RelationsKave Niksefat - SVP of Global Marketing and AccessPeter Griffith - EVP and CFOConference Call ParticipantsGeoff Meacham - Managing Director and Senior Biotech and Pharma AnalystGeoff MeachamHealthcare conference. My name's Geoff Meacham. I'm the Senior BioPharm Analyst. I have Jarway Fang with me from my team as well. So we're thrilled to have Amgen with us today. We have a c ...

Amgen (NasdaqGS:AMGN) FY 2025 Conference December 03, 2025 01:45 PM ET Company ParticipantsCasey Capparelli - VP of Investor RelationsKave Niksefat - SVP of Global Marketing and AccessPeter Griffith - EVP and CFOConference Call ParticipantsGeoff Meacham - Managing Director and Senior Biotech and Pharma AnalystGeoff MeachamHealthcare conference. My name's Jeff Meacham. I'm the Senior BioPharm Analyst. I have Jarway Fang with me from my team as well. So we're thrilled to have Amgen with us today. We have a co ...

Amgen (NasdaqGS:AMGN) FY Conference December 03, 2025 10:00 AM ET Company ParticipantsCasey Capparelli - VP of Investor RelationsPeter Griffith - EVP and CFOKave Niksefat - Senior VP of Global Marketing and AccessUmer Raffat - Senior Managing DirectorKave Niksefat - EVP and Chief Commercial OfficerUmer RaffatSuper excited to have Amgen Management with us. I'll let you guys kick things off, and we'll jump right in.Peter GriffithGreat. Umer, thank you so much for inviting us again. We're always pleased to be ...

Royalty Pharma (NasdaqGS:RPRX) FY 2025 Conference December 02, 2025 03:15 PM ET Company ParticipantsTerrance Coyne - CFOMarshall Urist - Head of Research and InvestmentsNone - ModeratorNoneBiopharma analyst and today we have Royalty Pharma, so we have Terry Coyne, CFO; Marshall Urist, EVP, Head of R&I, research and investments. Right. Once that R&D and people got really.Marshall UristKind of like hooked up, yeah.Yeah. Yeah.Okay.Dana like almost fired me. Yeah. So, I guess on the back of a very successful ye ...

Core Insights - Amgen reported Q2 earnings with a revenue increase of 9% year-over-year to $9.179 billion, exceeding market expectations of $8.94 billion [1] - Net profit surged 92% year-over-year to $1.432 billion, translating to earnings per share (EPS) of $2.65; adjusted EPS was $6.02, surpassing the market forecast of $5.29 [1] - Product sales rose by 9%, driven primarily by volume growth, although partially offset by a 3% decrease in net selling prices [1] Financial Performance - Revenue for the quarter was $9.179 billion, higher than the anticipated $8.94 billion [1] - Net profit reached $1.432 billion, a significant increase from the previous year [1] - Adjusted EPS was reported at $6.02, exceeding market expectations [1] Product Sales - Sales growth was primarily driven by volume increases, with 15 products achieving at least double-digit sales growth, including Repatha, Evenity, and Imdeltra [1] - The overall product sales increase was partially mitigated by a 3% decline in net selling prices [1] Outlook - Amgen raised its full-year revenue guidance to a range of $35 billion to $36 billion, up from the previous estimate of $34.3 billion to $35.7 billion, with market expectations at $35.4 billion [1] - Adjusted EPS guidance was also increased to a range of $20.2 to $21.3, compared to the prior forecast of $20 to $21.2, with market expectations at $20.91 [1]